Abstract
Atopic dermatitis (AD) is characterized by Staphylococcus aureus (SA) colonization, epithelial defects & type 2 immunity. Dupilumab (DPL), which blocks the biological actions of IL-4 & -13, provides an opportunity to probe the import of type 2 inflammation on microbial, epithelial & immune features of AD. To do this, the Atopic Dermatitis Research Network designed a 6wk, RDBPC trial with high density sampling (Days 0, 3, 7, 14, 21, 28 & 42) to quantify these changes & assess how they relate to disease severity (EASI, NRS, IGA & SCORAD).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
